6:26 PM
 | 
Jan 07, 2009
 |  BC Extra  |  Company News

Reloxin review extended

Ipsen (Euronext:IPN) said FDA extended the PDUFA date of a BLA for Reloxin botulinum toxin type A to treat glabellar lines...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >